ACM
HAE icon

Acrisure Capital Management’s Haemonetics HAE Stock Holding History

Acrisure Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,577
Closed -$213K – 97
2023
Q1 		$213K Buy
+2,577
New +$209K 0.22% 219

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acrisure Capital Management's HAE Position: Q2 2023 in Review

Acrisure Capital Management sold out of Haemonetics (HAE) in Q2 2023, closing a stake of 2,577 shares — an estimated $213K sold.

Acrisure Capital Management first reported a position in HAE in Q1 2023 and held it in 1 quarter. The position peaked at $213K in Q1 2023. 296 funds tracked by Wall St. Rank hold HAE as of Q2 2023.

  • Acrisure Capital Management reported no remaining Haemonetics position as of Q2 2023 after selling out during the quarter.
  • Acrisure Capital Management sold 2,577 Haemonetics shares in Q2 2023, an estimated $213K.
  • Acrisure Capital Management first reported a position in Haemonetics in Q1 2023 and held it in 1 quarter.
  • Acrisure Capital Management's Haemonetics position peaked at $213K in Q1 2023.
  • 296 funds tracked by Wall St. Rank held Haemonetics as of Q2 2023.

Based on Acrisure Capital Management's 13F filing for Q2 2023.